Nestlé strengthens dermatology unit

By

Sarah Ahssen

Published
Jun 9, 2014

Nestlé has announced the acquisition of the rights to commercialize products by Restylane, Perlane, Emervel, Dysport and Sculptra in Canada and the United States. Purchased from the Canadian firm Valeant Pharmaceuticals International, the deal totaled 1.4 billion dollars. According to Nestlé, the United States and Canada taken together represents half the global market for skin care.

In a bid to reinforce its position in the industry, Nestlé announced in February its intention to create Nestlé Skin Health, a company founded upon Galderma, the dermatology joint venture owned 50/50 by Nestlé and L'Oréal that will soon pass fully into the hands of the Swiss giant. The cession will also allow Nestlé to reduce its stake in L'Oréal.